Business Context and Reporting Period
Haleon plc, a global consumer-health company listed on the LSE and NYSE, filed this Form 6-K for February 2023. The filing reports the outcome of the tender process for the company’s statutory audit for the year ending December 31, 2023.
Haleon’s principal product categories include oral health, pain relief, respiratory health, digestive health, vitamins, minerals and supplements, and other consumer-health products.
Key Financial Metrics
The filing does not provide financial results, revenue, profit, cash flow, margins, debt, liquidity, or other operating metrics.
Material Changes
- Following a competitive audit tender and a recommendation from the Audit and Risk Committee, Haleon’s Board approved the proposed appointment of KPMG LLP as statutory auditor.
- KPMG’s appointment is subject to shareholder approval at Haleon’s 2023 Annual General Meeting.
- Deloitte LLP will remain the auditor through completion of the audit of Haleon’s accounts for the year ending December 31, 2022.
Outlook, Risks and Unusual Items
The filing contains no financial guidance or business outlook. The principal pending matter is shareholder approval of KPMG LLP’s appointment at the 2023 AGM. The company thanked Deloitte for its work, including support related to Haleon’s demerger and listing as an independent consumer-health company.
Investor Verification Points
- Verify shareholder approval of KPMG LLP at the 2023 Annual General Meeting.
- Confirm the completion and audit opinion for Haleon’s 2022 financial statements by Deloitte LLP.
- Review subsequent filings for any changes to the auditor appointment or related audit and accounting matters.